Inoue Masaya, Honma Yoshio, Urano Takeshi, Suzumiya Junji
Department of Oncology/Hematology, Faculty of Medicine, Shimane University, Izumo, Shimane 693-8501, Japan.
Department of Biochemistry, Faculty of Medicine, Shimane University, Izumo, Shimane 693-8501, Japan.
Oncol Lett. 2017 Jul;14(1):792-800. doi: 10.3892/ol.2017.6219. Epub 2017 May 19.
Bendamustine, a hybrid molecule of a purine analog and alkylator, induces cell death by the activation of apoptosis and the DNA damage response. The agent MK615 is produced from Japanese apricot and contains a number of cyclic triterpenes that exhibit antitumor activities. In the present study, the combined effects of bendamustine and MK615 on lymphoma cells were investigated. The combined compounds synergistically induced apoptosis in all lymphoid cell lines examined. MK615 inhibited the bendamustine-induced phosphorylation of checkpoint kinase 1 and 2. As ataxia telangiectasia mutated (ATM) and ataxia telangiectasia- and Rad3-related (ATR) kinases are key mediators of the DNA damage response, the effects of the combination of bendamustine and ATM/ATR inhibitors (KU-60019 and VE-821) on lymphoma cells were investigated. KU-60019 and/or VE-821 potentiated bendamustine activity in all cell lines tested, but did not affect MK615 activity, suggesting that these inhibitors have the same underlying mechanism of action as that of MK615. The results of the present study suggest that it may be feasible to use ATM/ATR inhibitors in combination with bendamustine for treating malignant lymphoma.
苯达莫司汀是一种嘌呤类似物与烷化剂的杂合分子,通过激活凋亡和DNA损伤反应诱导细胞死亡。药物MK615由杏仁制成,含有多种具有抗肿瘤活性的环状三萜。在本研究中,研究了苯达莫司汀和MK615对淋巴瘤细胞的联合作用。联合用药在所有检测的淋巴细胞系中协同诱导凋亡。MK615抑制苯达莫司汀诱导的检查点激酶1和2的磷酸化。由于共济失调毛细血管扩张症突变(ATM)激酶和共济失调毛细血管扩张症及Rad3相关(ATR)激酶是DNA损伤反应的关键介质,因此研究了苯达莫司汀与ATM/ATR抑制剂(KU-60019和VE-821)联合使用对淋巴瘤细胞的影响。KU-60019和/或VE-821在所有测试细胞系中增强了苯达莫司汀的活性,但不影响MK615的活性,这表明这些抑制剂与MK615具有相同的潜在作用机制。本研究结果表明,将ATM/ATR抑制剂与苯达莫司汀联合用于治疗恶性淋巴瘤可能是可行的。